Myanmar foreign investment bill in parliament again

YANGON (Reuters) - Myanmar's new foreign investment bill was with parliament on Thursday, after amendments to address concerns of foreign firms eager to enter the country, and it could be quickly approved and sent to the president to be signed into law, lawmakers said.

The bill has passed back and forth between the legislative and executive branches since March in a tussle involving a government eager to attract foreign investment, tycoons determined to protect their monopolies, and small businesses keen not to be shut out.

"The bill of the new Foreign Investment Law will be brought to the Union Parliament on November 1, where I think it will be passed after some discussion," Thein Nyunt, lower house law maker and leader of New National Democratic Party (NNDP), told Reuters.

"Since agreement had been reached between the bill committees of the upper and lower houses on the most important provisions, I am sure the bill will be approved," he added, without elaborating on the content of the bill.

A member of one of the committees, who attended an emergency meeting in October, also said agreement had been reached on the main provisions.

A clause requiring foreign investors to provide at least 35 percent of start-up capital in a joint venture with local partners had been dropped, he said, asking not to be named.

"Now it has been changed to 'the participation ratio of the joint venture is only to be decided by local and foreign partners'. It means anything they both agree," he said.

Another controversial provision stipulated that foreigners could only own 50 percent of a joint venture in certain sectors deemed sensitive.

"Now it has been decided not to mention this ratio in the Foreign Investment Law since it can sting foreign investors. Instead, the ratio will be mentioned only in the relevant rules and regulations, and only if necessary," the committee member said.

"These changes were initiated by the president, so I am sure he will sign the bill when it is sent to him," he added, suggesting that could happen in November.

President Thein Sein took office in March 2011 at the head of a quasi-civilian government that brought almost 50 years of military rule to an end.

He has undertaken economic and political reforms that have persuaded Western countries to suspend sanctions and prompted an upsurge of interest in the country by multinational firms, who see potential in its abundant resources and primitive economy.

(Editing by Alan Raybould and Robert Birsel)

Source: http://news.yahoo.com/myanmar-foreign-investment-bill-parliament-again-035654414--business.html

cesar chavez day raspberry ketone ron burgundy millennial media nit championship transcendentalism bells palsy

Archives Gig - Urbana, IL: Faculty, University of Illinois GSLIS

The Graduate School of Library and Information Science (GSLIS) at the University of Illinois seeks to hire an outstanding full-time faculty member to join our iSchool. Strong candidates in any area relating to the organization, management, preservation, and retrieval of information, and the production and transmission of knowledge are encouraged to apply. We are particularly interested in specializations that directly contribute to our leading program in data curation, including cyber- infrastructure, scientific data management, workflow systems, provenance, data archiving, data science, digital humanities, e-Research and e-Science, and semantic technologies. A focus on data in any area of science or scholarship, including the social sciences and the humanities, is relevant.

We especially welcome applications from members of under-represented groups working in these or other areas of library and information science. GSLIS is a highly interdisciplinary unit and the successful candidate could hold degrees in information science, a social science, cognitive science or psychology, computer science, the humanities, a natural science, or other relevant disciplines.

Ranked at no. 1 for many years GSLIS is an established national leader in both information science research and the preparation of information professionals. GSLIS offers MS and PhD degrees, a Certificate of Advanced Study (CAS), and participates in the University's undergraduate informatics minor, informatics PhD, and MS in Bioinformatics, and includes an award-winning online option (LEEP) for MS and CAS students. GSLIS faculty and students are involved in many initiatives across campus, including collaborations with world-renowned units such as the National Center for Supercomputing Applications (NCSA) and the Institute for Computing in Humanities, Arts, and Social Science (I-CHASS). Our close relationship with scientific and cultural institutions ensures that our research both shapes practice and engages critical contemporary problems.

At GSLIS data curation research and education is an area of emphasis for the Center for Informatics Research in Science and Scholarship (CIRSS). CIRSS supports an active portfolio of data curation research projects with a wide variety of institutional partners, collaborating with national data centers, other iSchools, leading research libraries, and cyberinfrastructure initiatives. GSLIS also sponsors data curation programs for both MS and PhD students. The GSLIS data curation specialization was the first LIS program to educate professionals in the curation of research data, providing students with the theory and skills necessary to work in the rapidly expanding number of academic and industry settings where this expertise is in demand. A specialization in data analytics, for both MS and PhD students, is also under development.

Appointment will begin August 16, 2013 or as negotiated. Rank is open, and salary commensurate with qualifications. A Ph.D. degree or equivalent is required although candidates near completion will be considered. To apply create a candidate profile at https://jobs.illinois.edu and upload a letter of application, curriculum vitae, short research statement, list of three references including contact information. To ensure full consideration applicants must apply by November 20, 2012. Applicants may be interviewed before that date, but no hiring decisions will be made until after the search closes.

More information about GSLIS programs and faculty can be found at http://www.lis.illinois.edu/. For further information regarding application procedures, contact Candy Edwards (cledward@illinois.edu, 217 244-3809). Illinois is an Affirmative Action/Equal Opportunity Employer and welcomes individuals with diverse backgrounds, experiences, and ideas who embrace and value diversity and inclusivity. (www.inclusiveillinois.illinois.edu).

Source: ARCAN listserv

Source: http://archivesgig.livejournal.com/733291.html

bobby valentine bobby valentine pbs nicki minaj miguel cabrera Karrueche Tran dodd frank

Scientists unravel resistance to breast cancer treatment

[ Back to EurekAlert! ] Public release date: 31-Oct-2012
[ | E-mail | Share Share ]

Contact: Aeron Haworth
aeron.haworth@manchester.ac.uk
44-161-275-8383
University of Manchester

Scientists have identified a molecular 'flag' in women with breast cancer who do not respond or have become resistant to the hormone drug tamoxifen.

Tamoxifen used alongside traditional chemotherapy and radiotherapy blocks the female hormone oestrogen that, in certain breast cancers, is required by the tumour to grow; it has been shown to improve cancer survival rates by up to one third.

However, about one third of patients with the appropriate type of breast cancer known as oestrogen receptor positive breast cancer do not respond to tamoxifen or develop resistance to the drug. Oestrogen receptor positive breast cancer is the most common form of the disease accounting for 70% of cases.

Now, a team from the University of Manchester's Paterson Institute for Cancer Research has identified a molecular flag or biomarker that will help doctors predict which patients will respond best to complementary (adjuvant) hormone therapy with tamoxifen.

"The identification of molecular flags to classify subgroups of breast cancer and so determine the best treatment for each patient is of increasing importance in cancer therapy," said study lead Professor Gran Landberg.

"Tamoxifen has been shown to be highly effective in some breast cancer patients when used alongside traditional cancer therapies but, in a third of cases, the result has not been what we would hope. If we can predict which patients will respond to tamoxifen, and those who won't, then this is clearly advantageous as it means the correct treatment is provided instantly which will improve disease outcomes."

The research, funded by the charity Breakthrough Breast Cancer and published in the journal PLoS One, looked at the connective tissue surrounding the tumour, which is known to send signals that help the cancer to grow. The team, part of the Manchester Cancer Research Centre, found that fibroblast cells the cells that make up connective tissue in our bodies differ in their characteristics from patient to patient and can give clues about tamoxifen treatment response

Co-author Dr Susann Busch said: "We analysed tissue samples from 564 women with invasive breast cancer, some of whom were given tamoxifen and some who weren't; this allowed us to make a comparison between treatment responses.

"We discovered that women who had low levels of a protein known as pERK in their cancer-associated fibroblasts did not respond to tamoxifen. Testing patients for the pERK flag could help doctors determine whether tamoxifen is an appropriate treatment for their patient or whether alternative therapies should be explored, so saving time and money."

The researchers now plan to further study molecular flags that are characteristic for cancer-associated fibroblasts. Understanding how fibroblasts help the tumour to grow will allow the development of new strategies to block their harmful signals and overcome drug resistance.

###

Notes for editors:

A copy of the paper, entitled 'Low ERK Phosphorylation in Cancer-Associated Fibroblasts Is Associated with Tamoxifen Resistance in Pre-Menopausal Breast Cancer' by Susann Busch et al, published in PLoS One, is available on request.

Reference for survival rate:

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Early Breast Cancer Trialists' Collaborative Group (EBCTCG)* Lancet 2005; 365: 1687


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


[ Back to EurekAlert! ] Public release date: 31-Oct-2012
[ | E-mail | Share Share ]

Contact: Aeron Haworth
aeron.haworth@manchester.ac.uk
44-161-275-8383
University of Manchester

Scientists have identified a molecular 'flag' in women with breast cancer who do not respond or have become resistant to the hormone drug tamoxifen.

Tamoxifen used alongside traditional chemotherapy and radiotherapy blocks the female hormone oestrogen that, in certain breast cancers, is required by the tumour to grow; it has been shown to improve cancer survival rates by up to one third.

However, about one third of patients with the appropriate type of breast cancer known as oestrogen receptor positive breast cancer do not respond to tamoxifen or develop resistance to the drug. Oestrogen receptor positive breast cancer is the most common form of the disease accounting for 70% of cases.

Now, a team from the University of Manchester's Paterson Institute for Cancer Research has identified a molecular flag or biomarker that will help doctors predict which patients will respond best to complementary (adjuvant) hormone therapy with tamoxifen.

"The identification of molecular flags to classify subgroups of breast cancer and so determine the best treatment for each patient is of increasing importance in cancer therapy," said study lead Professor Gran Landberg.

"Tamoxifen has been shown to be highly effective in some breast cancer patients when used alongside traditional cancer therapies but, in a third of cases, the result has not been what we would hope. If we can predict which patients will respond to tamoxifen, and those who won't, then this is clearly advantageous as it means the correct treatment is provided instantly which will improve disease outcomes."

The research, funded by the charity Breakthrough Breast Cancer and published in the journal PLoS One, looked at the connective tissue surrounding the tumour, which is known to send signals that help the cancer to grow. The team, part of the Manchester Cancer Research Centre, found that fibroblast cells the cells that make up connective tissue in our bodies differ in their characteristics from patient to patient and can give clues about tamoxifen treatment response

Co-author Dr Susann Busch said: "We analysed tissue samples from 564 women with invasive breast cancer, some of whom were given tamoxifen and some who weren't; this allowed us to make a comparison between treatment responses.

"We discovered that women who had low levels of a protein known as pERK in their cancer-associated fibroblasts did not respond to tamoxifen. Testing patients for the pERK flag could help doctors determine whether tamoxifen is an appropriate treatment for their patient or whether alternative therapies should be explored, so saving time and money."

The researchers now plan to further study molecular flags that are characteristic for cancer-associated fibroblasts. Understanding how fibroblasts help the tumour to grow will allow the development of new strategies to block their harmful signals and overcome drug resistance.

###

Notes for editors:

A copy of the paper, entitled 'Low ERK Phosphorylation in Cancer-Associated Fibroblasts Is Associated with Tamoxifen Resistance in Pre-Menopausal Breast Cancer' by Susann Busch et al, published in PLoS One, is available on request.

Reference for survival rate:

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Early Breast Cancer Trialists' Collaborative Group (EBCTCG)* Lancet 2005; 365: 1687


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Source: http://www.eurekalert.org/pub_releases/2012-10/uom-sur103112.php

alcatraz cruise ship martin luther king jr. zappos john elway john elway i have a dream speech

Your Car Insurance Plan ? Billy Roids

Posted in Home Insurance

Home Insurance Oxnard CA Every year, more cars and drivers hit the highways. With countless vehicles on the road, accidents will happen. Automobile insurance can be the difference between a small setback and a major hassle. How can you decide what insurance you require and how to buy it? Required coverage varies by state/province but usually includes the following:Pays for damages due to bodily injury and property damage to others for which you are responsible. Bodily injury damages include medical expenses, lost wages and pain and suffering. Property damage includes damaged property and loss of use of property. It also covers your defense and court costs if you are sued. State laws usually mandate minimum amounts, but higher amounts are available and usually recommended. Personal injury protection: This is required in some states and is optional in others. Sometimes referred to as no-fault coverage, this pays the medical treatment for you or your passengers regardless of who was at fault. It may also cover lost earnings, replacement of services and funeral expenses. State law usually sets minimum amounts. Medical payments: This coverage is available states that are not considered no-fault; it pays regardless of who may have been at fault. It pays for an insured person?s reasonable and necessary medical and funeral expenses for bodily injury from a crash. Collision: Pays for damage to your car caused by an accident. Comprehensive: Applies if your car is stolen or damaged by causes other than collision, including fire, wind, hail, flood or vandalism. Uninsured motorist: Pays for damages when an insured person is injured in a crash caused by another person who does not have liability insurance or by a person who cannot be identified (usually a hit-and-run driver). Under-insured motorist: Pays for damages when an insured person is injured in a crash caused by another person who does not have enough liability insurance to cover the full amount of the damages. Other coverage, such as emergency road service and car rental, is also available.What you pay for auto insurance varies by company and will depend on several factors, including: * What coverage you select * The make and model of the car you drive * Your driving record * Your age, gender and marital status and * Where you live Many people think of auto insurance as a necessary evil, but it can save your financial well-being. Evaluate your needs, do your research and with the support of your insurance agent make the decision that best suits you. Don?t leave your house unprotected

Comments are closed.-->

Source: http://billyroids.com/your-car-insurance-plan-10/

survivor south pacific survivor south pacific house of wax patrick willis team america snow day snow day

Gene signature predicts prostate cancer survival

ScienceDaily (Oct. 10, 2012) ? Researchers from Mount Sinai School of Medicine have identified a six-gene signature that can be used in a test to predict survival in men with aggressive prostate cancer, according to new research published in the October issue of The Lancet Oncology. This is the first study to demonstrate how prognostic markers may be useful in a clinical setting.

Using blood from 202 men with treatment-resistant prostate cancer, researchers found six genes characteristic of treatment-resistant prostate cancer. Men with the six-gene signature were high-risk, with a survival time of 7.8 months, and men without it were low-risk, with a survival time of approximately 34.9 months. A replication study of 140 additional patients validated these findings. William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology of The Tisch Cancer Institute at The Mount Sinai Medical Center, led the research team.

"There is an urgent need for predictive models that help assess how aggressive the disease is in prostate cancer patients, as survival can vary greatly," said Dr. Oh. "Our six-gene model, delivered in a simple blood test, will allow clinicians to better determine the course of action for their patients, determine clinical trial eligibility, and lead to more targeted studies in late-stage disease."

Until now, disease prognosis in advanced prostate cancer could only be determined through clinical predictors or, occasionally, tumor biopsies with only moderately predictive results. This study shows the efficacy of the six-gene model blood test in determining length of survival.

"The genes noted in the model suggest possible changes in the immune system related to late-stage disease that warrant further study as a target for immune-based therapies," said Dr. Oh.

Dr. Oh's team is conducting additional studies exploring the feasibility of the six-gene signature in other types of prostate cancer, the stability of the signature during the course of a patient's illness, and the predictive ability of this signature in patients with prostate cancer treated with immune-based therapies.

This work was done in collaboration with colleagues at Dana-Farber Cancer Institute in Boston and Memorial Sloan-Kettering Cancer Center in New York City.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:


Story Source:

The above story is reprinted from materials provided by Mount Sinai Medical Center, via Newswise.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


Journal Reference:

  1. Robert W Ross, Matthew D Galsky, Howard I Scher, Jay Magidson, Karl Wassmann, Gwo-Shu Mary Lee, Leah Katz, Sumit K Subudhi, Aseem Anand, Martin Fleisher, Philip W Kantoff, William K Oh. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. The Lancet Oncology, 2012; DOI: 10.1016/S1470-2045(12)70263-2

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Source: http://feeds.sciencedaily.com/~r/sciencedaily/health_medicine/genes/~3/MxdczsBDAt0/121010151234.htm

easter eggs pineapple upside down cake free ecards flying car masters golf tournament the replacements how to hard boil eggs

New Center: Concerns About Online Options for Special Ed. Students

By Nirvi Shah from On Special Education

Leaders of a new center designed to expand students with disabilities' access to online courses said in just a few months of work, they have some serious concerns about those students' participation in e-learning.

"Our preparatory investigations have already raised a number of concerns that we think are urgent enough to report even now," wrote Don Deshler of the Center for Research on Learning, David Rose of the Center for Applied Special Technology, Bill East of the National Association of State Directors of Special Education, and Diana Greer of the Center for Research on Learning, in an open letter written this month.

Read more HERE.

Source: http://mtdiablosped.blogspot.com/2012/10/new-center-concerns-about-online.html

detroit lions Aaron Paul ufc mumford and sons packers Dancing With The Stars All Stars Joseph Gordon-Levitt

Esquire/Yahoo poll: Obama, Romney would lose to Clinton, Reagan

When Yahoo News and Esquire commissioned a presidential poll in early September, we asked respondents their preference in two fantasy matchups: Barack Obama versus Ronald Reagan and Mitt Romney versus Bill Clinton. Across nearly every demographic, our poll has uncovered a strong pro-nostalgia bent in the electorate.

Reagan defeated Obama by 14 points, while Clinton outran Romney by 35 points. Even respondents who identified with the contemporary candidate?s party demonstrated flaky loyalty. Among the general population, 23 percent of Democrats chose Reagan over Obama while 28 percent of Republicans preferred Clinton to Romney.

When we pitted Clinton versus Reagan in the finals, however, the two ex-presidents were locked in a statistical tie, 49 to 46 percent in Clinton?s favor. The margin of error for the poll among the general population was 4 percentage points.

President-elect Clinton visits former President Reagan in Los Angeles in 1992 (Gary Hershorn/Reuters)

[See more analysis at Esquire.com.]

Today, Yahoo and Esquire are releasing the complete results of the poll, available for download here.

The poll was conducted by landline and cellular telephone Sept. 7-10, 2012, among a random national sample of 1,002 adults.

Source: http://news.yahoo.com/obama-romney-clinton-reagan-matchup-esquire-yahoo-news-poll-20121010.html

california earthquake tyson chandler tyson chandler stephen hill draft tracker the pirates band of misfits cleveland browns

Mother blames herself for son, 7, dying in north side fire - TODAY'S ...

CREATED Oct. 8, 2012 - UPDATED: Oct. 9, 2012

MILWAUKEE - A mother is blaming herself for the death of her seven year old boy during a fire early Saturday morning at a home on the city's north side.

Authorities say seven-year-old Joelle Creasy wasn't able to make it out of the burning home near N. 23rd St. and W. Auer Ave.

His mother, Tameshia Brice, was visiting family in New York when their house caught fire. She says she checked the smoke detector before she left.

"My batteries had died in my smoke detectors (so I) took them out and...I forgot to replace them."

The medical examiner's report says an adult relative started cooking food inside the home, then went upstairs, fell asleep and woke up to the smell of something burning.

That adult saw a fire started, then jumped off the roof of the home -- which is on the second floor -- and four children inside the home following him.

That adult and those four children weren't hurt during the escape.

Authorities believe the home is a total loss.

?

Source: http://www.todaystmj4.com/news/local/173172311.html

Griselda Blanco Michelle Obama Speech eva longoria Rihanna wiz khalifa Michael Clarke Duncan Nazanin Boniadi

American Obesity: The Biggest Threat To Fuel Economy?Your ...

From Forbes?..

As automakers shave every extra ounce from new vehicles to boost fuel economy, a weight problem of a different sort could be thwarting their efforts.

The extra pounds people are packing on their waistlines might be offsetting gains in gas mileage, according to a blog post from the insurance company Allstate.

Weight gain of passengers in noncommercial vehicles could account for nearly 1 billion gallons of gasoline consumed per year in the United States from 1960 to 2002, Allstate says in an infographic accompanying its blog post.

Automakers are doing all they can to make new vehicles lighter than in the past, including using lightweight material like thinner steel. The goal is to reduce how much fuel they use. For example, the 2013 Nissan Altima is about 80 pounds lighter than the model it replaces, and the 31 miles per gallon it gets in combined city and highway driving is about 15 percent better than the previous model.

It might seem preposterous that portly passengers could negate the weight savings automakers are achieving. But consider that fuel efficiency improves 2 percent for every 100 pounds shed from a vehicle, according to the U.S. Environmental Protection Agency. So if a heavyset adult couple?each 50 pounds overweight?loses the extra weight, their fuel economy will go up 2 percent.

The reason automakers are going to great lengths to make lighter vehicles?Jaguar even reduced the number of rivets it uses on cars?is to comply with stringent new Corporate Average Fuel Economy Standards. Fleet-wide fuel economy for passenger cars must jump to an average of 54.5 miles per gallon by 2025, from 32.8 miles per gallon this year.

To read the full story?..Click here

This entry was posted in Health / Fitness Articles and tagged Len Saunders, Obesity by Len Saunders. Bookmark the permalink.

Source: http://www.lensaunders.com/wp/?p=5371

epidemiology total eclipse of the heart jionni lavalle earthquake san francisco donald payne elizabeth berkley lenny dykstra